Management Change/Compensation (Form 8-K)

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

On April 8, 2026, Solana Company (the "Company") and Antonella Favit-Van Pelt, MD, PhD, mutually agreed that Dr. Favit-Van Pelt would separate from the Company and resign as the Company's Chief Medical Officer, effective as of April 8, 2026 (the "Effective Date"). In connection with her separation from the Company, the Company and Dr. Favit-Van Pelt entered into a separation agreement, effective as of the Effective Date (the "Separation Agreement").

Pursuant to the Separation Agreement, Dr. Favit-Van Pelt is entitled to a separation payment of $875,000, to be paid in a single lump sum payment, less applicable withholdings, to be made within ten business days after the Effective Date. In exchange for the consideration provided to Dr. Favit-Van Pelt pursuant to the Separation Agreement, Dr. Favit-Van Pelt agreed to waive and release any claims in connection with Dr. Favit-Van Pelt's employment and separation from the Company. Dr. Favit-Van Pelt must also continue to comply with the confidential information and invention assignment provisions set forth in Dr. Favit-Van Pelt's employment agreement with the Company.

The foregoing summary description of the terms of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, which is filed as Exhibit 10.1 hereto.